Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Non-Comparative, Two-Arm Open Label, Multiple-Center Study Of Cp-751,871 In Combination With Docetaxel/Prednisone In Chemotherapy- Naive (Arm A) And Docetaxel/Prednisone Refractory (Arm B) Patients With Hormone Insensitive Prostate Cancer.

Trial Profile

A Phase 2, Randomized, Non-Comparative, Two-Arm Open Label, Multiple-Center Study Of Cp-751,871 In Combination With Docetaxel/Prednisone In Chemotherapy- Naive (Arm A) And Docetaxel/Prednisone Refractory (Arm B) Patients With Hormone Insensitive Prostate Cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Figitumumab (Primary) ; Docetaxel; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 17 Feb 2014 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
  • 29 Aug 2012 New source identified and integrated (DRKS00004070: German Clinical Trials Register).
  • 29 Aug 2012 Planned number of patients changed from 120 to 204 as reported by German Clinical Trials Register.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top